Match Group Inc vs Revvity Inc — how do they compare? Match Group Inc trades at $41.48 (market cap $9.53B), while Revvity Inc trades at $152.05 (market cap $16.98B). The key difference: Revvity Inc is the larger of the two by market cap, and Match Group Inc pays the higher dividend (1.93%). Which is the better fit depends on your goals — on Pluang, investors hold Match Group Inc for 115 Days and Revvity Inc for 12 Days on average.
| MTCH | RVTY | |
|---|---|---|
Market Cap | $9.53B | $16.98B |
Volume | 3,228,794 | 1,456,900 |
Sector | Media | Health |
52-Week High | $44.40 | $157.36 |
52-Week Low | $28.90 | $82.26 |
Typical Hold Time | 115 Days | 12 Days |
Enterprise Value | $12.49B | $19.30B |
Dividend Yield | 1.93% | 0.18% |
Signals from Pluang's Aura AI — not financial advice
MTCH trades at $40.86, up 0.59% today, with a bullish technical signal and strong cash flow growth. The company reported a net income margin of 20.17% for 2025, with recent earnings beats in Q4 2025 and Q2 2026. Revenue remains stable at $3.49B, while analyst consensus is a Buy with a $42.29 price target. Positive sentiment is driven by margin expansion and Hinge's growth, though high debt levels and mixed quarterly results present some caution.
The outlook for MTCH is cautiously optimistic, with upside to the consensus target offering ~3.5% potential gain. Strengths include robust profitability, solid cash generation, and product innovation, but risks involve elevated debt, competitive pressures, and reliance on Tinder's turnaround. Investors should weigh strong fundamentals against execution risks in a dynamic dating app market.
RVTY trades at $153.60, up 0.2% today and near its 52-week high of $158.28 (Defense World, 2026-10-01). The stock shows a bullish technical trend with strong moving average signals and has beaten earnings estimates for three consecutive quarters. Recent developments include the launch of a CE-IVDR-certified T1D screening kit in Europe (Business Wire, 2026-09-24) and the acquisition of Human Cell Design to expand metabolic disease research tools (Business Wire, 2026-09-09).
The outlook is positive, supported by earnings momentum, strategic acquisitions, and analyst optimism. However, the stock trades at a premium valuation with a P/E of 73.15, and near-term risks include margin pressures in China and rich valuation limiting upside beyond consensus targets. Revenue stability but slight profit margin compression in 2026 warrants monitoring.
Trailing returns across standard periods
Latest headlines on both assets
Match Group is a provider of online dating products. The firm became public in 2015 and was more than 80% owned by IAC/InterActiveCorp until IAC spun it off in the second quarter of 2020. The company has a vast portfolio of different online dating service providers, including Tinder, Match.com, OkCupid, Plenty of Fish, and Meetic. Match Group has more than 45 brands of online dating sites and/or apps, from which it generates user fee revenue (95%) and advertising revenue (5%).
Read more on MTCH →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →